Fig. 3From: Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2Neutralizing and spike antibody titers after three vaccine doses, symptomatic and asymptomatic breakthrough infections Shown are NAb titers against the original Wild-type strain (A), the Delta variant (B), and the Omicron BA.1 variant (C) determined by 50% focus reduction neutralization test (FRNT50) using the serum at follow-up. Also shown are anti-spike antibody titers measured with the Abbott reagent (D) and the Roche reagent (E) using the serum at follow-up Patients with PCR-confirmed infection were all symptomatic (n = 7), while those with seropositive on any of anti-SARS-CoV-2 nucleocapsid protein assays (Abbott or Roche assays) at follow-up were all asymptomatic (n = 4)The bars indicate geometric mean titers, and I-shaped bars indicate its geometric standard deviations. The dushed horizontal lines indicate the LOD for FRNT50 (NT50 < 40) and Roche assay (U/mL > 25,000) in the present analysisStatistical significance was determined by Kruskal-Wallis and Dunn’s multiple comparison test (ns: not significant; *P < 0.05; **P < 0.01; ***P < 0.001)Abbreviations: AU, arbitrary units; COVID-19, coronavirus disease 2019; LOD, limits of detection; NT50, 50% neutralization titer; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Back to article page